Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products, Tissue Engineering Part B: Reviews, vol.21, issue.6, pp.560-71, 2015. ,
DOI : 10.1089/ten.teb.2015.0068
Assessing the economic challenges posed by orphan drugs, International Journal of Technology Assessment in Health Care, vol.22, issue.01, p.36, 2007. ,
DOI : 10.1016/0168-8510(93)90042-N
Performance-Based Risk-Sharing Arrangements???Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force, Value in Health, vol.16, issue.5, pp.703-719, 2013. ,
DOI : 10.1016/j.jval.2013.04.011
Risk-sharing Schemes Worldwide: A Landscape Analysis of Health Outcomes based Reimbursement Agreements (2010). https ,
Do the Current Performance-Based Schemes in Italy Really Work? ???Success Fee???: A Novel Measure for Cost-Containment of Drug Expenditure, Value in Health, vol.18, issue.1, pp.131-136, 2015. ,
DOI : 10.1016/j.jval.2014.09.007
Using Documents in Social Research, Sage, 2003. ,
DOI : 10.4135/9780857020222
Law???s performativities: Shaping the emergence of regenerative medicine through European Union legislation, Social Studies of Science, vol.42, issue.5, pp.753-774, 2012. ,
DOI : 10.1177/0162243908329188
Mapping the health research landscape in Sub-Saharan Africa: a study of trends in biomedical publications, Journal of the Medical Library Association : JMLA, vol.97, issue.1, pp.41-44, 2009. ,
DOI : 10.3163/1536-5050.97.1.007
Environmental Risk, Uncertainty, and Participation: Mapping an Emergent Epistemic Community, Environment and Planning A, vol.40, issue.12, pp.2990-3008, 2008. ,
DOI : 10.1007/978-94-011-0131-8_3
Introduction: Values and Valuations in Market Practice, Journal of Cultural Economy, vol.15, issue.4, pp.361-369, 2013. ,
DOI : 10.1086/226828
Google Scholar as a new source for citation analysis, Ethics in Science and Environmental Politics, vol.8, issue.1, pp.61-73, 2008. ,
DOI : 10.3354/esep00076
The expansion of Google Scholar versus Web of Science: a longitudinal study, Scientometrics, vol.29, issue.3, pp.1547-1565, 2014. ,
DOI : 10.1126/science.1058040
Google Scholar compared to Web of Science. A Literature Review, Nordic Journal of Information Literacy in Higher Education, vol.1, issue.1, pp.41-51, 2009. ,
DOI : 10.15845/noril.v1i1.10
Web of Science, or Google Scholar? A behind-the-scenes guide for life scientists. : So which is better: PubMed, Web of Science, or Google Scholar Challenges for the new Cancer Drugs Fund, Lancet Oncol, vol.17, issue.4, pp.416-424, 2016. ,
Conditional Approval: Japan Lowers the Bar for Regenerative Medicine Products, Cell Stem Cell, vol.16, issue.4, pp.353-359, 2015. ,
DOI : 10.1016/j.stem.2015.03.013
Adaptive Licensing, Documents/early_access_to_medicines_scheme .pdf 26 CASMIABPI-BIA-CASMI-Adaptive- Licensing-Meeting-Report.pdf 27 Life sciences UK. From vision to action: Delivery of the Strategy for UK Life Sciences, 2014. ,
The many faces of Innovation, A report for ABPI by the Office of Health Economics, 2012. ,
Office of Health Economics Maximising R&D Productivity: new initiatives and gaps in the analysis, ABPI, Adapting the innovation landscape, UK Biopharma R&D sourcebook 2015, pp.11-14, 2015. ,
Cell-based therapy technology classifications and translational challenges, Philosophical Transactions of the Royal Society B: Biological Sciences, vol.32, issue.1680, p.20150017, 1680. ,
DOI : 10.1108/S0731-2199(2010)0000022004
URL : http://rstb.royalsocietypublishing.org/content/royptb/370/1680/20150017.full.pdf
Are there specific translational challenges in regenerative medicine? Lessons from other fields, Regenerative Medicine, vol.2, issue.3, pp.885-895, 2015. ,
DOI : 10.1016/j.hlpt.2014.10.014
EU Marketing Authorisation of Orphan Medicinal Products and Its Impact on Related Research, European Journal of Health Law, vol.24, issue.5, pp.1-24, 2017. ,
DOI : 10.1163/15718093-12341439
Bringing regenerative medicines to the clinic: the future for regulation and reimbursement, Regenerative Medicine, vol.20, issue.10, pp.897-911, 2015. ,
DOI : 10.1016/j.jval.2014.08.1176
Pricing for Orphan Drugs, JAMA, vol.310, issue.13, pp.1343-1344, 2013. ,
DOI : 10.1001/jama.2013.278129
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers, BMC Health Services Research, vol.326, issue.1, p.153, 2010. ,
DOI : 10.1136/bmj.326.7385.388
Risk sharing agreements: with orphan drugs?]. Farm Hosp, pp.455-63, 2012. ,